Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Volume: 81, Issue: 1, Pages: e21 - e23
Published: Jul 1, 2020
Abstract
Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including...
Paper Details
Title
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Published Date
Jul 1, 2020
Volume
81
Issue
1
Pages
e21 - e23
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.